NL-OMON39702已完成不适用
A prospective, randomized, cross-over, single-blind, placebo-controlled study to assess the pharmacodynamic effects, pharmacokinetics and safety and tolerability of one dose of 30 mg ulipristal acetate (UPA) followed by the administration of 20 days of 75 µg desogestrel (DSG) - HRA121022-001
HRA Pharma0 个研究点目标入组 35 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Women between 18 and 35 years old
- •- No current use of hormonal contraception and having had at least one complete menstrual cycle since having stopped hormonal contraception
排除标准
- •- Any contraindications to DSG or POP
研究者
相似试验
尚未招募
4 期
A prospective, randomized, controlled, single blind clinical study of Shenqigui oral liquid for improving bone marrow suppression in patients with small cell lung cancer of Qi and yin defiGas-yin two impeved small cell lung cancerITMCTR2100004677Chengdu University of Traditional Chinese Medicine
进行中（未招募）
不适用
A randomized, prospective, cross-over, double blind, placebo-controlled multicentre study to assess the efficacy and tolerability of almotriptan 12.5 mg in the mild pain phase of Mestrual Migraine followed by an open follow-up evaluation to assess consistencyEUCTR2005-000244-90-ITALMIRALL PRODESFARMA160
已完成
不适用
The future of corneal refractive reshaping: can we control myopia or is the risk of corneal compromise too great?Progressing mild childhood myopiaEye - Diseases / disorders of the eyeACTRN12608000007336Prof Helen Swarbrick75
进行中（未招募）
1 期
A controlled, randomised, study investigating the pharmacokineticproperties (to see how active the study drug is in your blood and how long it takes for the study drug to get out of your blood) , surrogate efficacy and safety of Octafibrin compared to Haemocomplettan® P/ RiaSTAPTM in subjects with congenital fibrinogen deficiencyCongenital fibrinogen deficiency (afibrinogenaemia) defined as plasma fibrinogen activity and antigen at screening below detection limit (i.e. <20mg/dl)MedDRA version: 14.1Level: LLTClassification code 10052651Term: AfibrinogenaemiaSystem Organ Class: 100000004850EUCTR2011-002403-15-DEOCTAPHARMA AG22
进行中（未招募）
不适用
A controlled, randomised, study investigating thepharmacokinetic properties (to see how active the study drug is in your blood and how long it takes for the study drug to get out of your blood) ,surrogate efficacy and safety of Octafibrin compared toHaemocomplettan® P/ RiaSTAPTM in subjects with congenital fibrinogen deficiencyEUCTR2011-002403-15-ITOCTAPHARMA AG18